Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

World Health Organization. Global report on psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Accessed May 31, 2016. Kragballe, 2013, Long-term management of scalp psoriasis: perspectives from the international psoriasis council, J Dermatol Treat, 24, 188, 10.3109/09546634.2012.681017 Tan, 2012, Nail psoriasis: a review, Am J Clin Dermatol, 13, 375, 10.2165/11597000-000000000-00000 Chung, 2014, Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis, J Am Acad Dermatol, 71, 623, 10.1016/j.jaad.2014.04.063 Wozel, 2008, Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas, Clin Dermatol, 26, 448, 10.1016/j.clindermatol.2007.10.026 Nestle, 2009, Psoriasis, N Engl J Med, 361, 496, 10.1056/NEJMra0804595 Zheng, 2007, Interleukin-22, a THl7 cytokine, mediates IL-23-induced dermal inflammation and acanthosis, Nature, 445, 648, 10.1038/nature05505 Lyakh, 2008, Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans, Immunol Rev, 226, 112, 10.1111/j.1600-065X.2008.00700.x Reich, 2005, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial, Lancet, 366, 1367, 10.1016/S0140-6736(05)67566-6 Papp, 2005, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction, Br J Dermatol, 152, 1304, 10.1111/j.1365-2133.2005.06688.x Menter, 2008, Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial, J Am Acad Dermatol, 58, 106, 10.1016/j.jaad.2007.09.010 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Langley, 2014, Secukinumab in plaque psoriasis–results of two phase 3 trials, N Engl J Med, 371, 326, 10.1056/NEJMoa1314258 Griffiths, 2015, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials, Lancet, 386, 541, 10.1016/S0140-6736(15)60125-8 Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N Engl J Med, 373, 1318, 10.1056/NEJMoa1503824 Kopp, 2015, Clinical improvement in psoriasis with specific targeting of interleukin-23, Nature, 521, 222, 10.1038/nature14175 Sofen, 2014, Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis, J Allergy Clin Immunol, 133, 1032, 10.1016/j.jaci.2014.01.025 Gordon, 2015, A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis, N Engl J Med, 373, 136, 10.1056/NEJMoa1501646 Krueger, 2015, Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial, J Allergy Clin Immunol, 136, 116, 10.1016/j.jaci.2015.01.018 Papp, 2015, Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br J Dermatol, 173, 930, 10.1111/bjd.13932 Teng, 2015, IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nature Med, 21, 719, 10.1038/nm.3895 Reich, 2017, J Am Acad Dermatol, 76, 418, 10.1016/j.jaad.2016.11.042 Fredriksson, 1978, Severe psoriasis – oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 Rich, 2003, Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis, J Am Acad Dermatol, 49, 206, 10.1067/S0190-9622(03)00910-1 Finlay, 1994, Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Mathias, 2016, Measurement properties of a patient reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary, J Dermatol Treat, 27, 322, 10.3109/09546634.2015.1114567 Feldman, 2016, Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary, J Dermatol Surg, 20, 19, 10.1016/j.jdds.2015.07.004 Revicki, 2008, Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis, Dermatology, 216, 260, 10.1159/000113150 Viswanathan, 2015, Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis, J Dermatol Treat, 26, 235, 10.3109/09546634.2014.943687 Blauvelt, 2015, IL-23/IL-17A dysfunction phenotypes Inform possible clinical effects from anti-IL-17A therapies, J Investig Dermatol, 135, 1946, 10.1038/jid.2015.144 Aggarwal, 2003, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of Interleukin-17, J Biol Chem, 278, 1910, 10.1074/jbc.M207577200 Wilson, 2007, Development, cytokine profile and function of human interleukin 17–producing helper T cells, Nature Immunol, 8, 950, 10.1038/ni1497 Ness-Schwickerath, 2010, Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells, J Immunol, 184, 7268, 10.4049/jimmunol.1000600 Villanova, 2014, Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis, J Investig Dermatol, 134, 984, 10.1038/jid.2013.477 Ward, 2014, A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells, J Investig Dermatol, 134, 2305, 10.1038/jid.2014.216 Teunissen, 2014, Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients, J Investig Dermatol, 134, 2351, 10.1038/jid.2014.146 Blauvelt, 2007, New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A, and TGF-β1, Expert Rev Dermatol, 2, 69, 10.1586/17469872.2.1.69 2002 1998 1998 2015 2016 Papp, 2015, Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR), J Drugs Dermatol, 14, 706 Kimball, 2013, Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study, J Eur Acad Dermatol Venereol, 27, 1535, 10.1111/jdv.12046 Langley, 2015, Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up, Br J Dermatol, 172, 1371, 10.1111/bjd.13469